Literature DB >> 11521228

Intraductal papillary components in invasive ductal carcinoma of the pancreas are associated with long-term survival of patients.

N Fukushima1, M Sakamoto, K Mukai, Y Kanai, K Shimada, T Kosuge, S Hirohashi.   

Abstract

Most patients with pancreatic ductal carcinoma have a poor prognosis. However, in certain cases, 5-year survival can be achieved after surgical resection. Analysis of the pathologic findings associated with good survival rates will assist in identifying the optimum treatment. The clinicopathologic features of 67 patients who underwent surgical resection of ductal adenocarcinoma of the pancreas between 1990 and 1996 were reviewed and correlated with survival rates. There were 42 men and 25 women, with a mean age of 62.1 years (range, 44 to 82 years). The mean greatest diameter of the tumor was 4.3 cm (range, 1.5 to 11 cm). Nineteen patients (29.4%) survived more than 3 years, and 9 (13.2%) survived more than 5 years after surgical resection. The intraductal papillary component (IDPC) of the carcinoma was the main focus of the pathologic observations. IDPC was defined as intraductal papillary proliferative lesions seen in the tumor nodule with proliferative cells consistent with carcinomatous cellular atypia. IDPC was clearly present (++) in 24 patients and vaguely present (+) in 9 patients. Using the Mantel-Cox test, a statistically significant correlation was found between the presence of IDPC (either + or ++) and postoperative patient survival (P =.002). IDPC is a morphologic feature associated with longer patient survival and should be taken into consideration in assessing the pathway of tumor progression.

Entities:  

Mesh:

Year:  2001        PMID: 11521228     DOI: 10.1053/hupa.2001.26473

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  4 in total

1.  Macroscopic features predict outcome in patients with pancreatic ductal adenocarcinoma.

Authors:  Shutaro Hori; Kazuaki Shimada; Yoshinori Ino; Seiji Oguro; Minoru Esaki; Satoshi Nara; Yoji Kishi; Tomoo Kosuge; Yukinori Hattori; Aoi Sukeda; Yuko Kitagawa; Yae Kanai; Nobuyoshi Hiraoka
Journal:  Virchows Arch       Date:  2016-10-05       Impact factor: 4.064

2.  Novel xenograft and cell line derived from an invasive intraductal papillary mucinous neoplasm of the pancreas give new insights into molecular mechanisms.

Authors:  Stefan Fritz; Carlos Fernández-del Castillo; A John Iafrate; Mari Mino-Kenudson; Nancy Neyhard; Jennifer LaFemina; Amy Stirman; Andrew L Warshaw; Sarah P Thayer
Journal:  Pancreas       Date:  2010-04       Impact factor: 3.327

3.  The intraductal carcinoma component is a significant prognostic parameter in patients with invasive ductal carcinoma of the pancreas.

Authors:  Hiroshi Kawahira; Takahiro Hasebe; Taira Kinoshita; Satoshi Sasaki; Masaru Konishi; Toshio Nakagori; Kazuto Inoue; Tatsuya Oda; Shin-ichirou Takahashi; Takenori Ochiai; Atsushi Ochiai
Journal:  Jpn J Cancer Res       Date:  2002-10

4.  Pathological complete response (pCR) with or without the residual intraductal carcinoma component following preoperative treatment for pancreatic cancer: Revisiting the definition of "pCR" from the prognostic standpoint.

Authors:  Daisaku Yamada; Hidenori Takahashi; Kei Asukai; Shinichiro Hasegawa; Akira Tomokuni; Hiroshi Wada; Hirofumi Akita; Masayohi Yasui; Hiroshi Miyata; Osamu Ishikawa
Journal:  Ann Gastroenterol Surg       Date:  2019-09-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.